To address this concern and in the context of our promising anti-LAG3 data in MM, we went on to evaluate expression of LAG3 ligands, GAL-3 and HLA-DP/DQ/DR, on CD138+ MM cells in patient BMMC and MM cell lines, identifying them as promising therapeutic targets. Here, LGALS3 is linked to Miyoshi myopathy.